Sara De Dosso

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Federica Di Nicolantonio, Miriam Martini, Francesca Molinari et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +17

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

<i>PIK3CA</i> Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

Andrea Sartore‐Bianchi, Miriam Martini, Francesca Molinari et al. · Cancer Research · 2009 · 739 citations

Medicine, Oncology, Pharmacology +17

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

Bernhard Scheiner, Katharina Pomej, Martha M. Kirstein et al. · Journal of Hepatology · 2021 · 300 citations · Full text

Pharmacy, Immunology, Oncology +17